

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA of Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin’s lymphoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Axicabtagene ciloleucel would be administered at a designated CAR-T centre. As there are a limited number of centres, one stakeholder noted that it would be important to consider equal access for people having the treatment. According to the [NHS website](#), there are 9 CAR-T centres (not all provide adult services).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not considered to be an equalities issue that needs to be addressed by committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No additional stakeholders identified.

**Approved by Associate Director (name):** Jasdeep Hayre

19 October 2021